CAR-T therapy has transformed treatment for certain blood cancers. However, solid tumours present greater challenges. The immunosuppressive microenvironment and limited T-cell trafficking reduce effectiveness. Researchers therefore develop multiple strategies to overcome these barriers.
Solid tumours create a hostile local environment. Dense stroma, low oxygen levels, and inhibitory molecules restrict CAR-T cell function. Regulatory immune cells further suppress activity. As a result, infused cells often lose potency after reaching the tumour.
Trafficking into the tumour mass also remains inefficient. Many CAR-T cells fail to leave the bloodstream and infiltrate the tissue. Physical barriers and mismatched chemokine signals contribute to this problem. Therefore, improving both entry and survival inside the tumour becomes essential.
One major approach modifies the CAR-T cells themselves. Engineers equip cells with additional receptors that recognise tumour-associated chemokines. These changes help cells migrate more effectively toward the tumour site. Moreover, researchers add dominant-negative receptors or switch receptors that convert inhibitory signals into activating ones.
Armoured CAR-T cells represent another strategy. These cells secrete cytokines such as IL-12 or IL-15 locally. The released factors help remodel the microenvironment and support T-cell persistence. In addition, some designs include checkpoint inhibitors expressed on the CAR-T surface to block local suppression.
Combination therapies also show promise. Clinicians pair CAR-T infusion with agents that deplete regulatory T cells or myeloid-derived suppressor cells. Others combine treatment with oncolytic viruses or chemotherapy that softens the tumour stroma. Consequently, more CAR-T cells can enter and remain functional.
Local delivery methods offer further advantages. Direct injection into or near the tumour bypasses some trafficking barriers. This approach concentrates cells at the disease site and reduces systemic exposure. Meanwhile, regional administration has produced encouraging early results in certain solid tumours.
Multi-antigen targeting helps address tumour heterogeneity. Dual or tandem CARs recognise more than one target. This design lowers the chance that antigen-negative cells will escape. Furthermore, logic-gated CARs improve safety by requiring multiple signals before full activation.
Researchers continue to refine manufacturing and conditioning regimens. Improved lymphodepletion protocols create space for CAR-T expansion. Optimised cell products with younger, less exhausted phenotypes also perform better in solid tumour settings.
Overall, progress depends on addressing both trafficking and the immunosuppressive microenvironment together. Combined genetic, pharmacological, and delivery strategies currently offer the most promising path forward. Continued clinical evaluation will determine which approaches deliver durable benefit for patients with solid tumours.